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Background. Systemic inﬂammation may play a role in the development of idiopathic fatigue, that is, fatigue not
explained by infections or diagnosed chronic illness, but this relationship has never been investigated in community
studies including the entire adult age span. We examine the association of the inﬂammatory marker C-reactive protein
(CRP) and fatigue assessed annually in a 3-year outcome period for UK adults aged 16–98.
Methods. Multilevel models were used to track fatigue 7, 19, and 31 months after CRP measurement, in 10 606 UK indi-
viduals. Models accounted for baseline fatigue, demographics, health conditions diagnosed at baseline and during fol-
low-up, adiposity, and psychological distress. Sensitivity analyses considered factors including smoking, sub-clinical
disease (blood pressure, anaemia, glycated haemoglobin), medications, ethnicity, and alcohol consumption.
Results. Fatigue and CRP increased with age, and women had higher values than men. CRP was associated with future
self-reported fatigue, but only for the oldest participants. Thus, in those aged 61–98 years, high CRP (>3 mg/L) independ-
ently predicted greater fatigue 7, 19, and 31 months after CRP measurement [odds ratio for new-onset fatigue after 7
months: 1.88, 95% conﬁdence interval (CI) 1.21–2.92; 19 months: 2.25, CI 1.46–3.49; 31 months: 1.65, CI 1.07–2.54].
No signiﬁcant longitudinal associations were seen for younger participants.
Conclusions. Our ﬁndings support previously described CRP–fatigue associations in older individuals. However, there
are clear age modiﬁcations in these associations, which may reﬂect a contribution of unmeasured sub-clinical disease of
limited relevance to younger individuals. Further work is necessary to clarify intervening processes linking CRP and
fatigue in older individuals.
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Introduction
Idiopathic fatigue and possible causes
In healthy individuals, fatigue is usually experienced
as a transient response to physical exertion or pro-
longed activity, which reduces with rest and does not
normally interfere with daily tasks (Kluger et al.
2013). However, it can also be persistent, and not
clearly attributable to exertion: this kind of ongoing
fatigue can disrupt quality of life, as well as social or
occupational functioning (Finsterer & Mahjoub, 2014).
It is a substantial driver of contact with primary care
services, estimated as the primary reason for around
6.5% of general practitioner visits, and a secondary rea-
son for a further 19% of visits (Cullen et al. 2002). While
fatigue is more commonly reported by women than
men (Newton & Jones, 2010; Blackwell & Clarke,
2013), its relationship with age is unclear; some studies
report age-related increases in reported fatigue, but
others report age-related decreases (Blackwell &
Clarke, 2013; Dolan & Kudrna, 2015). Fatigue is some-
times a consequence of chronic illnesses; it is a com-
mon symptom of conditions including cancer (Bower,
2014), Parkinson’s disease (Friedman et al. 2007), and
diabetes (Lasselin et al. 2012). However, in studies of
primary care patients presenting with fatigue, diagno-
ses of relevant underlying illness are subsequently
made only in a minority of cases (Nijrolder et al.
2009) and only slightly more than for controls (Stadje
et al. 2016). Hence, many cases of fatigue have no obvi-
ous explanation, and as such are termed ‘idiopathic’
(Alexander et al. 2010). It has been suggested that low-
grade inﬂammatory activity may play a role in other-
wise unexplained fatigue (Cho et al. 2009; Alexander
et al. 2010; Cho et al. 2013), based on experiments show-
ing that exogenous inﬂammatory agents can induce
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fatigue in healthy humans (Spath-Schwalbe et al. 1998),
and the fact that fatigue is a key component of the
‘sickness behaviour’ triggered by the acute inﬂamma-
tory response to infection or injury (Dantzer et al.
2008; Miller et al. 2009). From this, it has been proposed
that ‘systemic’, ‘chronic’ or ‘low-grade’ inﬂammation –
a milder, temporally extended analogue of the acute
inﬂammatory response to infection or injury that
occurs in the absence of these triggers (Pearson et al.
2003) – may be involved in the development of idio-
pathic fatigue. Typically higher in women, systemic
inﬂammation increases with age (Krabbe et al. 2004).
Though associated with many chronic illnesses (Gan
et al. 2004; Dowlati et al. 2010), systemic inﬂammation
can also occur in the absence of disease; it is strongly
and positively inﬂuenced by smoking and adiposity
(Hamer et al. 2009; Howren et al. 2009), with associa-
tions also shown for stressful events and experiences
(Yudkin et al. 2000; Steptoe et al. 2007).
Previous studies of inﬂammation and idiopathic
fatigue
Most existing studies on inﬂammatory markers and
fatigue are of limited relevance to idiopathic fatigue,
describing associations with fatigue severity in the con-
text of cancer, multiple sclerosis or other speciﬁc ill-
nesses using small clinical samples (Bower, 2014;
Patejdl et al. 2016). In community samples, inﬂamma-
tion–fatigue associations may still be confounded by
chronic illness; a reverse-causal pathway from fatigue
to inﬂammation may also operate via reductions in
physical activity, which has anti-inﬂammatory effects
(Valentine et al. 2011). Longitudinal analysis can help
clarify these issues by modelling later fatigue as a func-
tion of earlier inﬂammation, with adjustment for
chronic illness. Since fatigue-like symptoms form part
of depressive symptomatology, with which a more
general association of systemic inﬂammation is estab-
lished (Dowlati et al. 2010), associations must also be
shown to be independent of depressive symptoms.
Lastly, since both fatigue and inﬂammatory activity
are elevated following injury or infection (Vollmer-
Conna et al. 2004), steps must be taken to isolate
systemic inﬂammation from transient processes.
Typically, researchers exclude participants with
C-reactive protein (CRP) >10 mg/L (Pearson et al.
2003), although this cut-off may be conservative (Ishii
et al. 2012).
To our knowledge, only two longitudinal studies
have examined inﬂammation–fatigue associations in
large community samples. The ﬁrst, based on 2983 US
adults aged 33–45, reported that the inﬂammatory
marker CRP was associated with fatigue 5 years
later and vice versa, which the authors interpret as
supporting a bidirectional relationship (Cho et al.
2009). The second, in 4847 British Civil servants aged
39–63, found onset of fatigue during a 3-year follow-up
was predicted by higher levels of two inﬂammatory
markers (CRP and interleukin-6) at baseline (Cho et al.
2013). While these studies are consistent with a role
for systemic inﬂammation in idiopathic fatigue, they
had several shortcomings. Firstly, since neither study
excluded participants with very high CRP values, asso-
ciations may have been inﬂated by infection- or
injury-related fatigue, rather than the chronic processes
ostensibly under investigation. Secondly, both samples
were considerably age-restricted, meaning this relation-
ship is yet to be examined in individuals younger than
33 or older than 63. Thirdly, since both studies consider
only a single follow-up point, the temporal evolution of
fatigue following systemic inﬂammation is unknown.
Given the high possibility of confounding and reverse
causation in this relationship, mapping such ‘trajector-
ies’ across multiple follow-up points could be illuminat-
ing, since a pattern of decreasing associations may
indicate reverse causation or confounding by undiag-
nosed conditions at baseline. As the 2013 study
adjusted for chronic illness diagnosed before baseline
but not during follow-up, previously reported inﬂam-
mation–fatigue associations in middle age may have
been inﬂated by chronic disease not yet diagnosed at
baseline. We aim to ﬁll these gaps using data from a
large, nationally representative survey of UK adults
aged 16–98. Using three follow-up points, we map tra-
jectories of fatigue 1, 2, and 3 annual waves after CRP
measurement; exclude individuals with signs of acute
inﬂammation; consider newly diagnosed conditions at
each follow-up point; and explore differential effects
by age and gender.
Methods
Participants
The UKHLS is an annual longitudinal survey of over
40 000 UK households, beginning in 2009–2010. It com-
prises a general population sample (GPS), a stratiﬁed
clustered random sample of households representative
of the UK population, and a smaller component from
the pre-existing British Household Panel Survey
(BHPS) (Knies, 2015). Annual interviews collecting
sociodemographic information are conducted through-
out each year, usually in the same month for each par-
ticipant. Biomedical measures and blood samples were
collected during a single nurse visit, which took place
in the participant’s home 5 months after the annual
wave 2 interview (GPS participants, 2010–2012) or
wave 3 interview (BHPS participants, 2011–2013)
(McFall et al. 2014).
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Ethical approval for the Understanding Society
nurse visit was obtained from the National Research
Ethics Service (Reference: 10/H0604/2). Participants
gave written consent for blood sampling (McFall
et al. 2014). Respondents were eligible for a nurse
visit if they had taken part in that wave’s main inter-
view in English; were aged 16+; lived in England,
Wales or Scotland; and were not pregnant. Of 35 875
participants meeting these requirements, 57.5% took
part. The initial sample for this analysis was deﬁned
as participants present at the biomedical assessment
and at least one subsequent wave. Of 19 769 partici-
pants in the initial sample, 12 429 (62.9%) had usable
CRP measurements. Missingness was usually due to
non-consent for blood samples, more rarely because
participants were taking anti-coagulant drugs, had a
bleeding disorder or other reasons; details are pro-
vided in the user guide (Benzeval et al. 2014). Three
hundred and sixty lacked a usable fatigue measure-
ment at follow-up, and 870 were excluded for missing
covariates. Excluding 593 participants with CRP >10
mg/L, including 399 between 10 and 20 mg/L, left a
ﬁnal sample of 10 606 participants and 28 407
observations.
Measures
CRP
CRP was analysed from serum by Newcastle upon
Tyne Hospitals NHS Foundations Trust, using the
high-sensitivity N Latex CRP mono Immunoassay on
the Behring Nephelometer II Analyser. Intra-assay
coefﬁcients of variation were <2% (Benzeval et al.
2014). For analysis, CRP was categorised as low
(<1.00 mg/L), medium (1.00–2.99 mg/L), and high
(3.0–10.0 mg/L), in accordance with the Centres for
Disease Control and Prevention/American Heart
Association recommendations (Pearson et al. 2003)
and previous analysis on this topic (Cho et al. 2009).
Fatigue
At each wave, participants completed the 12-item ver-
sion of the Short Form Health Survey (SF-12), designed
to capture overall health, pain, fatigue, and health-
related limitations to functioning in persons over 14
(Ware & Sherbourne, 1992). In the 12-item version,
fatigue is indexed by a single item: ‘How much of the
time during the past 4 weeks did you have a lot of energy?’
This is one of four vitality sub-scale questions from the
36-item version of the Short Form Health Survey
(SF-36), of which the 12-item version has been shown
to be a reasonable substitute (Jenkinson et al. 1997),
and the same question used in a previous longitudinal
analysis on this topic (Cho et al. 2009). Participants
could respond using options listed on a showcard: all
of the time; most of the time; some of the time; a little
of the time; none of the time. As responses were
ordered and their distribution approximated a normal
curve, fatigue was considered a quasi-interval variable
and treated as continuous in linear regressions, consist-
ent with the procedure of the earlier study (Cho et al.
2009). For each time point, a binary fatigue measure
was formed by combining participants who reported
having a lot of energy ‘a little of the time’ and ‘none
of the time’ into a high-fatigue group, and participants
who reported having a lot of energy ‘all’, ‘most’, or
‘some’ of the time into a low-fatigue group. This
allowed analysis of onset of binary fatigue during fol-
low-up, an approach taken by the other existing paper
on this topic (Cho et al. 2013). For descriptive purposes,
‘low’-, ‘mid’-, and ‘high’-fatigue groups were deﬁned
as participants reporting having a lot of energy ‘all’
or ‘most’ of the time; ‘some’ of the time; or ‘a little’
or ‘none’ of the time.
Covariates
All models took account of baseline fatigue from the
annual interview 5 months before CRP measurement.
Hence, linear models adjusted for baseline fatigue,
while in logistic models of binary fatigue onset, ana-
lysis was restricted to people without binary fatigue
at baseline. Age and gender were reported by ques-
tionnaire at the biomedical assessment, with age ter-
tiles calculated as 16–43, 44–60, and 61–98; within
each tertile age in years was adjusted for. Equivalised
household income was derived from questionnaire
information from the annual interview corresponding
to the biomedical assessment, from which age-band-
speciﬁc quartiles were calculated. Recent diagnoses at
baseline of relevant somatic illness were derived
using questionnaire information from UKHLS W1
and W2 (GPS participants) or BHPS W18, UKHLS
W1, and UKHLS W2 (BHPS participants). This
included asthma, emphysema, chronic bronchitis, can-
cer, cardiac problems, high blood pressure, and dia-
betes. The role of new somatic illness was explored
using diagnoses of these conditions plus arthritis at
each follow-up wave. Arthritis at baseline could not
be included, as the BHPS component of the sample
was not asked about arthritis until UKHLS W2. All
models adjusted for psychological distress at outcome,
using a summary score (possible range 0–36) from the
12-item General Health Questionnaire (GHQ). Baseline
body mass index (BMI) was calculated from height and
weight measured by the nurse at the biomedical visit,
using a portable stadiometer, and the Tanita BF522
digital ﬂoor scale, respectively (McFall et al. 2014).
BMI was classiﬁed using WHO categories:
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recommended weight (18.5–24.9), overweight (25.0–
29.9), obese (530) or underweight (<18.5). At the
nurse assessment, participants were asked to name
up to 22 currently prescribed medicines, and con-
tainers checked by the nurse. Medications potentially
affecting CRP included non-steroidal anti-inﬂamma-
tory medications (NSAIDs), statins, corticosteroids,
oral contraceptives, and hormone replacement therapy
(HRT). Self-reported ethnicity was categorised as white
(British, Irish or other white) and any other ethnicity,
including mixed (3.8% of the ﬁnal sample). Glycated
haemoglobin (HbA1c) was deﬁned as normal (<42
mmol/mol), prediabetes (42–47 mmol/mol), and dia-
betes (548 mmol/mol). Hypertension (5140 systolic,
590 diastolic) was calculated from blood pressure
measured by the nurse, using the Omron HEM 907
machine. Anaemia, from blood samples, was deﬁned
as a haemoglobin value <12 g/dL for women and
<13 g/dL for men. Information on smoking and alcohol
consumption came from wave 2 questionnaires for all
participants. We used both drinking frequency (days
in the past week when alcohol was consumed, cate-
gorised as none, 1–2, 3–4, or 5+) and the maximum
alcoholic units consumed on any day of the past 7
(none/44.0/4.1–6.0/6.1–8.0/8.1–10.0/10.1–15.0/>15.0).
Analysis
In adjusted cross-sectional models, signiﬁcant inter-
action terms between CRP categories (low/medium/
high) and both age in years (p = 0.001, p < 0.001 for
medium*age and high*age, respectively) and age ter-
tiles (p = 0.06, p = 0.02, p = 0.06, p = 0.009 for medium*
44–60, medium*61–98, high*44–60, and high*61–98,
respectively) pointed to age modiﬁcation, but there
was no evidence of gender interaction (p = 0.39 for
medium*female and 0.76 for high*female). Longitu-
dinal models were therefore calculated separately by
age tertiles, but not gender.
To map trajectories of CRP–fatigue associations,
fatigue measurements 1, 2, and 3 annual waves post-
baseline were modelled as functions of CRP 5 months
after baseline fatigue, such that outcome points were 7,
19, and 31 months after CRP measurement. Data were
reshaped to make each outcome fatigue measurement
a separate observation, and a repeated-measures,
multilevel panel data structure speciﬁed, with fatigue
measurements 7, 19, and 31 months after CRP meas-
urement nested within a level representing indivi-
duals. To separately investigate trajectories by age
tertile, a three-way interaction term was used, linking
age tertiles (16–43, 44–60, and 61–98), CRP groups
(<1.00, 1.00–2.99, 3.00–10), and waves since baseline.
Models treating fatigue continuously used STATA’s
xtreg command; models investigating odds of binary
fatigue onset used STATA’s xtlogit command, and
were restricted to individuals without binary fatigue
at baseline (N = 8531). Age in years, gender, household
income, BMI, baseline fatigue, and somatic illnesses at
baseline were included as time-invariant covariates,
GHQ at outcome and new diagnoses during follow-up
as time-varying covariates. Unbalanced data were
allowed, meaning participants were included even if
not present at all outcome waves. All analyses used
robust standard errors to account for survey effects.
Sensitivity analyses
Since the threshold of CRP 10 mg/L for separating
chronic from infection-related inﬂammation may be
conservative (Ishii et al. 2012), we repeated analyses
including 399 individuals with CRP between 10 and
20 mg/L. Additional adjustment explored the impact
of time of day, season, and processing time of blood
samples, plus several factors with substantial add-
itional missingness: HbA1c, hypertension, anaemia
status, and alcohol consumption measures. Further
sensitivity analyses examined the impact of anti-
inﬂammatory medications, oral contraceptives, and
HRT by excluding participants taking these medica-
tions. Only 3.8% of participants deﬁned as non-white
or mixed ethnicity, precluding adjustment for ethni-
city, so its impact was explored by excluding the
small group of non-white or mixed participants.
Smoking inﬂuences CRP, and may therefore indirectly
affect fatigue via CRP. For this reason, smoking was
not included as a covariate in the main models to
avoid overadjustment (i.e. adjustment for a variable
upstream of the exposure on the causal pathway),
but its impact was explored in two sensitivity analyses.
In the ﬁrst, we adjusted for ﬁve-category smoking sta-
tus (never, ex-, and banded current), and in the second
current smokers were excluded entirely.
Results
Descriptive
Participants excluded for missing data, compared to
those retained, did not differ signiﬁcantly by gender
or BMI. However, they were older (41.0% v. 33.4%
aged 61–98, mean age 54.8 v. 51.6), with slightly higher
CRP (2.13 v. 2.01 mg/L), and slightly higher fatigue at
all points (e.g. 2.86 v. 2.66 at baseline). They were
more likely to have a long-term illness at baseline
(35.6% v. 30.8%) and to be taking CRP-relevant medi-
cation (26.9% v. 20.3%). Participants excluded for
CRP >10 mg/L were more often female (63.9% v.
55.3%), older (40.6% v. 33.4% aged 61–98, mean age
54.6 v. 51.6), heavier (BMI 31.4 v. 27.8), with greater
fatigue at all points (e.g. 3.08 v. 2.66 at baseline).
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They were more likely to have a long-term illness at
baseline (45.7% v. 30.8%), to be taking CRP-relevant
medications (32.0% v. 20.3%), and to smoke (25.8% v.
18.3%). Their CRP ranged from 10.1 to 228 mg/L,
with a mean of 22.7 mg/L.
In the ﬁnal sample, CRP increased with age, and in
every age group was higher for women than men;
mean CRP values for men aged 16–43, 44–60, and
61–98 were 1.45, 1.90, and 2.16 mg/L, and for women
aged 16–43, 44–60, and 61–98, they were 1.91, 2.08,
and 2.44 mg/L. However, within CRP categories,
mean CRP was comparable across age tertiles: mean
low, mid, and high CRP values for the 16–43 group
were 0.48, 1.71, and 5.16; for the 44–60 group, they
were 0.52, 1.74, and 5.18; and for the 61–98 group,
they were 0.57, 1.76, and 5.18.
Fatigue increased with age, and within each age
group women reported more fatigue than men. At
baseline, the proportion of participants reporting bin-
ary fatigue was: 11.5% (men aged 16–43 years),
13.3% (women 16–43), 16.6% (men 44–60), 16.9%
(women 44–60), 19.5% (men 61–98), and 21.7%
(women 61–98). Table 1 shows sample descriptive
characteristics by fatigue level. Participants experien-
cing greater fatigue were more likely to have diag-
nosed illnesses at baseline, take anti-inﬂammatory
medications, smoke regularly and more heavily, have
extreme BMIs including underweight, and have
HbA1c levels indicating prediabetes or diabetes (p
values from χ2 for trend all <0.05). Fatigue did not dif-
fer signiﬁcantly by ethnicity, blood pressure or use of
oral contraceptives or HRT.
Cross-sectional models
For participants aged 16–43, neither medium nor high
CRP was associated with greater fatigue [coeff: −0.02,
conﬁdence interval (CI) 0.08–0.22, p = 0.46 and coeff:
0.06, −0.2 to 0.13, p = 0.12, respectively]. For partici-
pants aged 44–60, high CRP was associated with
greater fatigue (coeff: 0.15, CI 0.08–0.22); for partici-
pants aged 61–98, medium and high CRP were asso-
ciated with greater fatigue (coeff: 0.08, CI 0.02–0.14,
coeff: 0.19, 0.12–0.27). Only when participants with
CRP between 10 and 20 mg/L were included, signiﬁ-
cant cross-sectional associations were seen with high
CRP in every age group (coeff: 0.07, CI −0.00 to 0.14,
p = 0.05), 44–60 (coeff: 0.17, CI 0.10–0.24, p < 0.001),
and 61–98 (coeff: 0.22, CI 0.15–0.29, p < 0.001) (Table 2).
Longitudinal models
In adjusted multilevel models, signiﬁcant CRP-associated
elevations were seen only for participants aged 61–98
(Table 3), for whom high CRP (>3 mg/L) was signiﬁcantly
associated with elevated fatigue at all follow-up points,
and mid-CRP (1.00–3.00 mg/L) associated with elevated
fatigue at the second and third outcome points. While
CIs overlapped, the association with high CRP decreased
across follow-up, from 0.16 (CI 0.10–0.23) one wave post-
baseline to 0.08 (CI 0.01–0.16) three waves post-baseline,
but the association with mid-CRP did not [0.02 (CI
−0.03 to 0.08) one wave post-baseline, 0.07 (CI 0.01–0.13)
two waves post-baseline, and 0.09 (CI 0.00–0.18) three
waves post-baseline]. Similarly, signiﬁcant CRP-associated
elevation in odds of fatigue onset was seen only for parti-
cipants aged 61–98, and only with high CRP. The associ-
ation strengthened at the second outcome point, from
odds ratio (OR) 1.88 (CI 1.21–2.92) to OR 2.25 (CI 1.46–
3.49) before falling to OR 1.65 (CI 1.07–2.54).
Sensitivity analyses
Including participants with CRP 10–20 mg/L, in the
44–60 group, high CRP predicted higher fatigue only
at the second outcome point in linear (coeff 0.07, CI
0.00–0.13, p = 0.04) and logistic models (OR 1.56, CI
1.02–2.36, p = 0.04), with no associations seen in the
16–43 group. Only by imposing no upper limit for
CRP, and with diagnoses during follow-up ignored,
did high CRP in the 44–60 group predict 1, 2, and 3
waves later, both elevated fatigue (coeff 0.06, CI 0.00–
0.12, p = 0.05; coeff: 0.09, CI 0.02–0.15, p = 0.009; coeff:
0.07, 0.01–0.15, p = 0.03), and new-onset fatigue (OR
1.52, CI 0.97–2.39, p = 0.07; OR 1.72, CI 1.14–2.58, p =
0.009; OR 1.70, CI 1.10–2.61, p = 0.01). Minimal differ-
ences were made by adjustment for ﬁve-group smok-
ing status, time of day, season and processing time of
blood samples, and for anaemia status, HbA1c, nurse-
measured blood pressure, and both measures of alco-
hol intake (online Supplementary Tables S1 and S2).
Conclusions were unaffected by exclusion of non-
white or mixed participants, participants taking medi-
cations, and current smokers.
Discussion
We ﬁnd the association of fatigue and CRP levels indi-
cative of systemic inﬂammation to be substantially
modiﬁed by age. Thus in cross-sectional models, both
medium and high CRPs are associated with fatigue
in participants aged 61–98, only high CRP is associated
with fatigue in participants aged 44–60, and neither is
associated with fatigue in participants aged 16–43, des-
pite comparable within-group CRP values across age
tertiles. Longitudinally, both medium and high CRPs
predict elevated fatigue, and high CRP predicts odds
of new-onset fatigue, in participants aged 61–98 fol-
lowing adjustment for a wide variety of covariates.
No such associations are seen in younger groups.
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Table 1. Descriptive characteristics of analytic sample (N = 10 606) by fatigue at baseline
Low fatiguea Mid fatiguea High fatiguea
Baseline characteristics Mean (S.D.) Mean (S.D.) Mean (S.D.)
Age (years) 50.6 (16.3) 51.7 (17.1) 54.3 (17.4)
GHQ score (possible range 0–36) 8.9 (3.6) 11.5 (4.7) 16.0 (7.0)
C-reactive protein (%) (%) (%)
Low (<1 mg/L) 44.8 37.2 31.3
Mid (1–2.99 mg/L) 37.9 38.5 37.3
High (3.0–10.0 mg/L) 17.3 24.3 31.5
Gender
Male 48.8 42.7 36.8
Female 51.2 57.3 63.3
Ethnicity
White (British/Irish/other white) 95.4 95.6 96.5
Any other ethnicity 3.8 3.9 3.2
Missing 0.8 0.5 0.3
Somatic diagnoses (respiratory disease, cancer, cardiac disease, high blood
pressure, diabetes)
No 76.6 66.1 53.3
Yes 23.4 33.9 46.7
Body mass index
<18.5 2.3 3.7 5.6
18.5–24.9 32.8 27.0 22.8
25.0–29.9 41.8 38.2 32.5
30–34.9 17.0 21.3 22.8
>35 6.1 9.9 16.2
Smoking status
Never 55.2 52.0 45.5
Ex 27.2 27.6 29.8
Current,410/day 8.4 9.6 9.9
Current, 11–20/day 6.2 7.9 10.2
Current, >20/day 1.1 1.3 2.7
Missing 1.9 1.6 1.9
Takes NSAIDs, corticosteroids or statins
No 84.9 78.5 66.9
Yes 15.1 21.5 33.1
Takes HRT or oral contraceptives
No 94.0 94.5 94.4
Yes 6.0 5.5 5.6
Anaemia (haemoglobin <12 g/L for women, <13 g/L for men)
No 85.1 83.8 79.5
Yes 8.4 9.5 13.1
Missing 6.5 6.7 7.5
Hypertension (5140 systolic,590 diastolic)
Normotensive untreated 58.5 52.6 43.4
Normotensive treated 8.6 13.2 17.2
Hypertensive 4.1 4.2 4.3
Missing 28.9 30.0 35.1
Glycated haemoglobin
Normal (<42 mmol/mol) 85.1 81.3 73.8
Prediabetes (42–47 mmol/mol) 5.4 7.3 9.5
Diabetes (548 mmol/mol) 3.1 5.2 9.3
Missing 6.4 6.3 7.5
GHQ, General Health Questionnaire.
a Fatigue groups categorised as: low fatigue: a lot of energy ‘all’ or ‘most’ of the time; mid fatigue: a lot of energy ‘some’ of
the time; high fatigue: a lot of energy ‘a little’ or ‘none’ of the time.
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Cross-sectional associations
The cross-sectional associations observed in the middle
and oldest age groups are consistent with previous
studies reporting cross-sectional CRP–fatigue associa-
tions (Cho et al. 2009; Cho et al. 2013). However, an
association in younger participants emerged only
with inclusion of participants with CRP of 10–20 mg/
L. This suggests that the association reported in a
previous study may at least partly reﬂect transient
inﬂammation due to current infections or injury.
Alternatively, a threshold effect may exist, with chron-
ically elevated CRP in younger individuals associated
with fatigue only at very high values. Discrepant
results may also relate to differing characteristics of
participants in the UK and America, for instance differ-
ent BMI proﬁles for this age group. In the previous
study (Cho et al. 2009), mean BMI for participants
reporting low, intermediate, and high fatigue were
27.6, 29.1, and 30.7 kg/m2, respectively. In our sample,
mean BMI in equivalent groups aged 33–45 were lower
at 27.3, 28.6, and 28.4 kg/m2.
Longitudinal associations
In men and women aged 61–98, high CRP (3–10 mg/L)
predicted higher fatigue and increased odds of binary
fatigue onset 7, 19, and 31 months later. Results in this
group are therefore consistent with previous longitu-
dinal studies reporting robust predictive associations
at single outcome points 3 or 5 years later (Cho et al.
2009, 2013), and indicate that predictive associations
are visible earlier than previously shown. Building on
those studies, we do not see declining CRP–fatigue
associations after the ﬁrst outcome measurement at 7
months, a pattern which would suggest reverse
causation, that is, inﬂuence of fatigue on CRP. CRP–
fatigue associations in the 61–98 group were robust
to adjustment for GHQ, and hence do not appear to
simply reﬂect a broader connection between inﬂamma-
tion and psychological distress. We were able to show
that CRP–fatigue associations in this group are inde-
pendent of chronic disease diagnoses during follow-up
as well as at baseline, with sensitivity analyses indi-
cating they are independent of smoking, and various
aspects of sub-clinical health. Since participants
excluded due to missing data were older and in poorer
health than those retained, with higher CRP and
greater fatigue, any bias from their exclusion is likely
to have underestimated associations in that group,
such that estimates are conservative.
Age modiﬁcation
An unexpected result was the lack of longitudinal
CRP–fatigue associations for participants aged 60 or
younger. This contrasts with previous studies using
similar fatigue measures, reporting associations in par-
ticipants aged 33–45 (Cho et al. 2009) and 39–63 (Cho
et al. 2013). A crucial difference is that unlike those
studies, we excluded participants with CRP values
indicative of acute inﬂammation in order to focus on
chronic processes. We also adjusted for chronic illness
diagnosed during follow-up. Including CRP between
10 and 20 mg/L, high CRP predicted fatigue only at
the second outcome point for those aged 44–60. Only
with no upper limit for CRP, and diagnoses during
follow-up ignored, did high CRP in the 44–60 group
predict elevated fatigue at all outcome points. Our
results therefore suggest previously reported longitu-
dinal CRP–fatigue associations in middle age,
interpreted as evidence for a role of systemic inﬂam-
mation itself in fatigue development, may have been
inﬂated by infection-related sickness behaviour and/
or chronic illness soon to be diagnosed.
Why would CRP linked to chronic processes be
clearly associated with future fatigue only in older
individuals? Like in the previous studies, CRP was cal-
culated from a single measurement. This may have
biased downwards CRP–fatigue associations, since a
single measurement of an inﬂammatory marker leads
to more ‘noise’ than when two measurements are aver-
aged (Kivimaki et al. 2014). However, it is unclear why
such measurement error would affect estimates only in
younger groups. Since our fatigue measure was a sub-
jective, self-reported measure, it is possible that
younger and older participants interpreted or
responded to the question in systematically different
ways, a phenomenon observed for more global assess-
ments of health (Shooshtari et al. 2007). This could pro-
duce different observed relationships, even if the
Table 2. Fully adjusted cross-sectional associations of C-reactive
protein (CRP) and fatiguea
CRP category Coeff CI p
Age 16–43
Mid (1.00–2.99 mg/L) −0.02 −0.08–0.03 0.46
High (3.00–10.0 mg/L) 0.06 −0.02–0.13 0.12
Age 44–60
Mid (1.00–2.99 mg/L) 0.05 −0.01–0.11 0.06
High (3.00–10.0 mg/L) 0.15 0.08–0.22 <0.001
Age 61–98
Mid (1.00–2.99 mg/L) 0.08 0.02–0.14 0.01
High (3.00–10.0 mg/L) 0.19 0.12–0.27 <0.001
a Adjusted for age in years, gender, long-term illness, psy-
chological distress, BMI and household income.
Low CRP (<1.00 mg/L) is the reference in all models.
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Table 3. Multilevel models
Fully adjusted associations of CRP and fatigue: 1, 2, and 3 waves post-baselinea (N = 10 606)
Tertile 1: 16–43
N = 3473
1 wave later (7 months after CRP measurement) 2 waves later (19 months after CRP measurement) 3 waves later (31 months after CRPmeasurement)
CRP category Coeff CI p Coeff CI p Coeff CI p
Mid (1.00–2.99 mg/L) 0.00 −0.06 to 0.05 0.91 0.00 −0.05 to 0.06 0.86 0.03 −0.03 to 0.09 0.34
High (3.00–10.0 mg/L) 0.05 −0.02 to 0.12 0.14 −0.00 −0.07 to 0.07 0.99 0.04 −0.03 to 0.11 0.27
Tertile 2: 44–60
N = 3588
1 wave later (7 months after CRP measurement) 2 waves later (19 months after CRP measurement) 3 waves later (31 months after CRPmeasurement)
CRP category Coeff CI p Coeff CI p Coeff CI p
Mid (1.00–2.99 mg/L) 0.01 −0.04 to 0.06 0.65 0.03 −0.02 to 0.08 0.29 0.05 −0.03 to 0.14 0.23
High (3.00–10.0 mg/L) 0.03 −0.03 to 0.10 0.30 0.05 −0.02 to 0.12 0.16 0.02 −0.04 to 0.09 0.46
Tertile 3: 61–98
N = 3545
1 wave later (7 months after CRP measurement) 2 waves later (19 months after CRP measurement) 3 waves later (31 months after CRPmeasurement)
CRP category Coeff CI p Coeff CI p Coeff CI p
Mid (1.00–2.99 mg/L) 0.02 −0.03 to 0.08 0.45 0.07 0.01 to 0.13 0.03 0.09 0.00 to 0.18 <0.05
High (3.00–10.0 mg/L) 0.16 0.10 to 0.23 <0.001 0.14 0.06 to 0.21 <0.001 0.08 0.01 to 0.16 0.03
Fully adjusted associations of CRP and onset of fatigue: 1, 2, and 3 waves laterb (N = 8813)
Tertile 1: 16–43
N = 2968
1 wave later (7 months after CRP measurement) 2 waves later (19 months after CRP measurement) 3 waves later (31 months after CRPmeasurement)
CRP category OR CI p OR CI p OR CI p
Mid (1.00–2.99 mg/L) 0.77 0.53–1.11 0.17 0.86 0.56–1.27 0.45 1.17 0.79–1.72 0.43
High (3.00–10.0 mg/L) 0.73 0.45–1.17 0.19 0.89 0.56–1.41 0.62 1.39 0.89–2.17 0.15
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biological processes involved do not differ by age.
Since this study’s outcome was self-reported fatigue
and not fatigability, it is also possible that age-group
differences in physical activity – which is tiring, but
also has anti-inﬂammatory effects – may have mod-
iﬁed inﬂammation–fatigue associations. Since objective
measures of physical activity (e.g. from pedometer
readings) were not available in this dataset, this
hypothesis cannot be tested further in this study popu-
lation. A ﬁnal possibility is that inﬂammation–fatigue
associations in older participants are explained by
aspects of sub-clinical disease by which younger peo-
ple are only rarely affected. Although we examined
several potential biological mediating pathways –
blood pressure, HbAa1c, haemoglobin levels – and
found they did not explain associations, other plaus-
ible pathways could not be examined as they were
not measured in the study. A plausible candidate is
atherosclerosis, given that inﬂammation is involved
in the formation of arterial plaques (Libby, 2012); it is
for this reason, it is believed, that inﬂammatory mar-
kers independently predict cardiac events among
apparently healthy people (Bassuk et al. 2004). If idio-
pathic fatigue in older people is explained by athero-
sclerosis, of which CRP is an established marker
(Kivimäki et al. 2008), we speculate that fatigue may
be an underappreciated and easily obtainable measure
of sub-clinical cardiovascular health for this age group.
However, the lack of prospective CRP–fatigue associa-
tions for participants aged 60 or younger, unless very
high CRP measurements are included, suggests that
the role of systemic inﬂammation itself in the develop-
ment of fatigue, at least in middle-aged, may have been
previously overstated.
Limitations
This analysis has several considerable strengths. Unlike
previous longitudinal studies, we excluded partici-
pants with CRP >10 mg/L to focus speciﬁcally on
chronic inﬂammatory processes. Examining the inﬂam-
mation–fatigue relationship across the whole adult
lifespan for the ﬁrst time, we were able to describe
when an association of fatigue and chronic inﬂamma-
tion becomes apparent. Unlike previous studies, we
were able to describe trajectories of CRP–fatigue asso-
ciations across three follow-up points, considering a
wide variety of confounding factors including onset
of new disease.
Use of the SF-12’s single-item fatigue measure, and
not the four-item sub-scale from the SF-36, was a limi-
tation; different relationships could exist between CRP
and the other fatigue dimensions of feeling ‘tired’,
‘worn out’, and ‘full of life’. The lack of CRP at
follow-up meant the reverse pathway (fatigue toT
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CRP) could not be simultaneously explored, and we
could not include diagnoses at baseline of arthritis.
The lack of measures such as intima media thickness
(for atherosclerosis), objective physical activity, and
fatigability in this dataset meant hypotheses around
age-related differences in sub-clinical health, activity
levels, and reporting could not be further explored.
Investigation in other datasets will be required to clar-
ify intervening processes linking CRP and fatigue in
older individuals.
Conclusions
In a large community sample, self-reported fatigue was
clearly associated with the inﬂammatory marker CRP
only for older participants (aged 61–98). This may
reﬂect a link in older people via sub-clinical illnesses,
which become more common through the lifespan.
However, the lack of CRP–fatigue associations at
younger ages suggests involvement of systemic in-
ﬂammation per se in fatigue development among
working-age adults may be less than previously
thought, or emerge only at very high CRP levels.
Previously reported associations in mid-life may have
been overestimated, inﬂated by infection-related sick-
ness behaviour or undiagnosed illnesses at baseline.
Further research is needed to clarify mechanisms
responsible for the CRP–fatigue association in older
individuals.
Supplementary Material
The supplementary material for this article can be
found at https://doi.org/10.1017/S0033291717002872.
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